Drug Profile

TNX 1600

Alternative Names: D-578; TNX-1600

Latest Information Update: 28 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wayne State University
Developer Tonix Pharmaceuticals Holding Corp
Class Amines; Anxiolytics; Benzothiazoles; Fluorobenzenes; Pyrans; Small molecules
Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jun 2023 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (PO)
31 Dec 2021 Tonix Pharmaceuticals has patent protection for TNX 1600 in USA
12 Sep 2019 Chemical structure information added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com